Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

Summary

The state of Maryland is taking a major step to rein in the cost of prescription medications. The Maryland Prescription Drug Affordability Board recently decided to set a strict price limit on Ozempic, a widely used treatment for type 2 diabetes. By establishing what is known as an upper payment limit, the board aims to make the medication more affordable for state budgets.

Under this new rule, the cost of Ozempic will be capped at $274 for a standard 30-day supply. To come up with this number, the board looked at the maximum fair price that Medicare currently pays for the drug and used it as a benchmark. State officials estimate that this single price cap will save Maryland about $5.8 million every year.

However, everyday consumers will not see these savings immediately. The initial price cap is slated to take effect in January 2027, and it will strictly apply to state and local government health plans. This means the immediate financial relief is limited to public programs rather than individual pharmacy visits for the general public.

Why it matters.

This decision represents a growing movement among individual states to take the high cost of prescription drugs into their own hands. While the initial Ozempic price cap is limited to government purchasers, it lays the groundwork for much broader changes. The Maryland board already plans to expand these price limits to include high-cost medications in the regular commercial insurance market beginning in 2028.

If successful, this phased rollout could eventually lower out-of-pocket costs for ordinary Marylanders who rely on private health insurance. It also sends a strong signal to the pharmaceutical industry that states are willing to use aggressive regulatory tools to control healthcare spending. As more states watch the Maryland experiment unfold, similar affordability boards could emerge nationwide, potentially transforming how essential treatments are priced across the country.

From the source

The story in numbers.

Price cap for a 30-day supply: $274
Estimated annual savings: $5.8 million
Implementation year for state and local governments: 2027

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

FDA shakeups, safety warnings, and a promising obesity pill

The Food and Drug Administration is navigating major leadership transitions, with acting directors Tracy Beth Høeg and Katherine Szarama recently exiting their roles in top drug review offices. Amidst these changes, the agency is facing severe safety concerns regarding Tavneos, a rare disease medication from the pharmaceutical company Amgen. In Japan, twenty patients taking the drug have died, with most of these deaths linked to a severe liver condition called vanishing bile duct syndrome. Following these tragedies and allegations of manipulated clinical trial data, the FDA has asked Amgen to withdraw the drug in the United States, though it currently remains available on the market. In other medical developments, an experimental daily pill for obesity is showing significant promise. Vincentage Pharma reported that patients taking its drug VCT220 in a late-stage Chinese clinical trial lost about twelve percent of their body weight over a year, compared to just one percent for those taking a placebo. However, the drug is still experimental globally, and a broader Phase 2 study is underway with results not expected until late 2026. Meanwhile, the major drugmaker Regeneron has teamed up with an early-stage startup called Parabilis Medicines. They plan to develop new therapies known as "antibody-helicon conjugates," which are designed to reach and treat disease-causing proteins inside cells that conventional methods have traditionally found impossible to target.

BioPharma Dive2 min read

Physical decline starts at 35, but late-in-life exercise boosts fitness

A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by. However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age. While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.

Science Daily1 min read

The $60 billion Chinese drug boom dividing the US biotech industry

United States pharmaceutical companies and biotechnology startups are buying up Chinese drug molecules at an unprecedented rate. In just the first three months of 2026, American firms spent $60 billion on these pharmaceutical components. This spending pace is on track to double the total from last year, which itself was already ten times higher than the amount spent in 2021. For American businesses, acquiring these Chinese drugs makes obvious practical sense. It allows them to stock their development pipelines quickly and at a much lower cost than developing the compounds entirely from scratch. Ultimately, this fast-tracked process could speed up how quickly new medicines reach patients worldwide who desperately need them. Despite the clear business advantages, this heavy reliance on foreign laboratories is creating a deep rift in the corporate community. Industry leaders are fiercely debating whether Chinese firms should be treated as essential partners or direct competitors. It is worth noting that these insights rely on a limited sample of just over a dozen executive interviews, and the staggering financial figures come from state-reported data, but the tension in the biotech field is palpable.

STAT News1 min read

Follow your curiosity.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

The $60 billion Chinese drug boom dividing the US biotech industry

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

The $60 billion Chinese drug boom dividing the US biotech industry

A little science goes a long way.